ANGPTL3 and metabolic syndrome: In dyslipidemic mice, inhibition of ANGPTL3 with evinacumab, an antibody against ANGPTL3, caused a dramatic decrease in atherosclerotic lesion area and necrotic content in animal models of dyslipidemia.